cp wire

CP Wire Articles

Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating Xtandi (enzalutamide)... read more

Thu, 12/20/18 - 10:19 am
Relay Therapeutics Banks $400 Million in Series C Round



On 12/20/18, Relay Therapeutics announced the successful completion of a $400 million Series C financing.

Relay Therapeutics combines unprecedented computational power with leading... read more

Thu, 12/20/18 - 09:57 am
Equillium's EQ001 Granted FDA Fast Track Designation for Acute Graft-Versus-Host Disease

Equillium, Inc. (Nasdaq: EQ) announced on 12/19/18 that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EQ001 for the treatment of acute graft-versus-host... read more

Wed, 12/19/18 - 10:15 am
Auron and Elucidata Launch AI Driven Collaboration to Identify Targets for Differentiation-Based Oncology Therapies

Auron Therapeutics and Elucidata Corporation on 12/19/18 announced a scientific collaboration using Elucidata’s AI-based target discovery platform to identify and validate targets for... read more

Wed, 12/19/18 - 10:00 am
Annexon Biosciences Closes $75 Million Series C Round

Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, announced on 12/19/18 that... read more

Wed, 12/19/18 - 09:39 am

Pages